Trial Profile
A Phase II Study of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Appendiceal cancer; Colorectal cancer
- Focus Therapeutic Use
- 26 Sep 2022 Status changed from completed to discontinued.
- 19 May 2021 Status changed from recruiting to completed.
- 12 Jan 2021 Planned primary completion date changed from 1 Nov 2020 to 1 Apr 2021.